Skip to content

Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

Phase 3, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03600376
Enrollment
17
Registered
2018-07-26
Start date
2018-08-19
Completion date
2019-08-14
Last updated
2021-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exertional Heat Stroke

Brief summary

A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.

Detailed description

Following triage and primary assessment in the emergency medical facility, subjects will be randomized to 1 of 2 treatment arms, SOC plus Ryanodex or SOC only. Subjects will be dosed and followed for up to 6 hours post-randomization. Current SOC is limited to body cooling and supportive measures.

Interventions

DRUGRyanodex and Standard of Care

Ryanodex to be administered as a rapid IV push

OTHERStandard of Care

Body cooling measures and supportive measures

Sponsors

Eagle Pharmaceuticals, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Intervention model description

Ryanodex (dantrolene sodium) for injectable suspension plus Standard of Care

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Core body temperature of greater than or equal to 40.0 degrees C (104 degrees F); recent history of exertional activity; GCS score less than 13; tachycardia -

Exclusion criteria

clinical severe infection; hyperthermia secondary to another condition; endotracheal intubation;; sedative drugs administered prior to or at time of study entry; likelihood of head trauma within 6 months pre-study; positive pregnancy test; history of myocardial infection within 30 days; history of seizure disorder or epilepsy; concomitant or prior use of calcium channel blockers. \-

Design outcomes

Primary

MeasureTime frameDescription
Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization]90 minutes post-randomizationThe GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).

Secondary

MeasureTime frameDescription
Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Treatment duration, up to 6 hoursThe GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).

Countries

Saudi Arabia

Participant flow

Participants by arm

ArmCount
Ryanodex and Standard of Care
In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered. Ryanodex and Standard of Care: Ryanodex to be administered as a rapid IV push
9
Standard of Care Only (SOC)
Standard of Care treatment will consist of the immediate start of cooling measures. Standard of Care: Body cooling measures and supportive measures
8
Total17

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event11
Overall StudyDetermined to be ineligible for study01
Overall StudyInvestigator Decision04
Overall StudyTransferred to other facility10

Baseline characteristics

CharacteristicStandard of Care Only (SOC)Ryanodex and Standard of CareTotal
Age, Continuous53.4 years
STANDARD_DEVIATION 11.2
55.3 years
STANDARD_DEVIATION 7.2
54.4 years
STANDARD_DEVIATION 9
BMI33.2 kg/m^2
STANDARD_DEVIATION 5.7
32.4 kg/m^2
STANDARD_DEVIATION 5.9
32.7 kg/m^2
STANDARD_DEVIATION 5.6
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants3 Participants3 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
8 Participants6 Participants14 Participants
Glasgow Coma Scale Score5.5 units on a scale
STANDARD_DEVIATION 2.7
5.6 units on a scale
STANDARD_DEVIATION 2.7
5.5 units on a scale
STANDARD_DEVIATION 2.6
Height159.3 cm
STANDARD_DEVIATION 7.7
162.8 cm
STANDARD_DEVIATION 7.6
161.3 cm
STANDARD_DEVIATION 7.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
4 Participants6 Participants10 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants2 Participants6 Participants
Race (NIH/OMB)
White
0 Participants1 Participants1 Participants
Rectal Temperature41.3 Degrees Celsius
STANDARD_DEVIATION 0.9
41.8 Degrees Celsius
STANDARD_DEVIATION 1.2
41.5 Degrees Celsius
STANDARD_DEVIATION 1.1
Region of Enrollment
Saudi Arabia
8 participants9 participants17 participants
Sex: Female, Male
Female
5 Participants7 Participants12 Participants
Sex: Female, Male
Male
3 Participants2 Participants5 Participants
Weight84.2 kg
STANDARD_DEVIATION 12.9
86.1 kg
STANDARD_DEVIATION 16.9
85.2 kg
STANDARD_DEVIATION 14.7

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 8
other
Total, other adverse events
7 / 95 / 8
serious
Total, serious adverse events
1 / 92 / 8

Outcome results

Primary

Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization]

The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).

Time frame: 90 minutes post-randomization

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization]4 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13 [Time Frame: 90 Minutes Post-randomization]2 Participants
Secondary

Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]

The GCS is a validated and reliable scale to evaluate level of consciousness in patients with acute brain injury. The scale assesses 3 functions: Eye Opening, Verbal Response, and Motor Response. GCS scores range from 15 (best) to 3 (worst).

Time frame: Treatment duration, up to 6 hours

Population: the outcome measure data table below is a summary of results showing the cumulative proportion of subjects achieving GCS score ≥13 post-randomization at all planned time points. Data is cumulative therefore the counts in the categories below will not add up to the Number Analyzed.~score ≥ 13 post-randomization at all planned time points in the study is shown

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 at 30 min. post-randomization1 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 90 min. post-randomization4 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 60 min. post-randomization2 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ to 13 after 2 hr.. post-randomization5 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 45 min. post-randomization1 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 4 hr. post-randomization/follow-up phase5 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 75 min. post-randomization3 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 at end of study or early termination5 Participants
Ryanodex and Standard of CareCumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 at 15 min post-randomization1 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 at end of study or early termination2 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 at 15 min post-randomization0 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 at 30 min. post-randomization0 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 45 min. post-randomization0 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 60 min. post-randomization1 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 75 min. post-randomization2 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 90 min. post-randomization2 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ to 13 after 2 hr.. post-randomization2 Participants
Standard of Care Only (SOC)Cumulative Incidence of Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) Greater Than or Equal to 13 Over the Course of the Study [Time Frame: Study Duration]Pts. achieving GCS score ≥ 13 after 4 hr. post-randomization/follow-up phase2 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026